EyePoint Stock

EyePoint EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of EyePoint (EYPT) as of Aug 4, 2026 is -4.40. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -7.34 — a change of -40.08% (higher).

EV/EBIT

-4.40

YoY

-40.08%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of EyePoint is 2026 -4.40 . EV/EBIT (Enterprise Value to EBIT) of EyePoint was 2025 -7.34 . It decreases by -40.08% higher compared to the previous year.

The EyePoint EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-1.85 base
Jan 1, 2020
-1.42 base
Jan 1, 2021
-4.27 base
Jan 1, 2022
-0.74 base
Jan 1, 2023
-7.37 base
Jan 1, 2024
-3.30 base
Jan 1, 2025
-6.23 base
Jan 1, 2026 (e)
-573.65 base
YEARPRICE-TO-EBIT
2026 est -573.65
2025 -6.23
2024 -3.30
2023 -7.37
2022 -0.74
2021 -4.27
2020 -1.42
2019 -1.85
2018 -3.88
2017 -1.47
2016 -1.52
2015 12.54
2014 -5.08
2013 -5.05
2012 -0.63
2011 -1.31
2010 5.91
2009 -8.05
2008 -0.39
2007 -0.92
2006 -1.60
Access this data via the Eulerpool API

EyePoint Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides EyePoint's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates EyePoint's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots EyePoint's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if EyePoint grows earnings faster than its peers.

EyePoint Stock analysis

What does EyePoint do? EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EyePoint stock

EV/EBIT (Enterprise Value to EBIT) of EyePoint is -4.40 in 2026.

EV/EBIT (Enterprise Value to EBIT) of EyePoint changed from -7.34 to -4.40, representing a -40.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) EyePoint since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s EyePoint with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — EyePoint

All Key Metrics — EyePoint